Hospitals Tara Bannow STAT Plus: Dana-Farber CEO on Mass General split: Boston needed a dedicated cancer hospital
Health Felice J. Freyer — Boston Globe STAT Plus: A fraught question for the children of Alzheimer’s: Is it coming for us?
Health Tech Mohana Ravindranath STAT Plus: How doctors and nurses shape Google’s AI, DEA extends telehealth flexibilities
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024
Adam's Take Adam Feuerstein STAT Plus: Bristol ‘take-under’ of Mirati is not so great for biotech, but company’s new cancer target has potential
Biotech Matthew Herper STAT Plus: Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies
Business Andrew Joseph STAT Plus: A Q&A with the global head of Boehringer Ingelheim’s innovation unit
Pharma Matthew Herper STAT Plus: Bristol Myers to buy cancer player Mirati for more than $4.8 billion
Biotech Elaine Chen STAT Plus: Inflammation gets its own research center, thanks to Chan Zuckerberg Initiative
Health Angus Chen STAT Plus: Long underappreciated, gamma-delta T cells may be key to colon cancer defense, study says
Pharmalot Ed Silverman STAT Plus: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems
First Opinion Vijay Ramakrishnan STAT Plus: How payer-participating trials could help transform clinical research on FDA-approved drugs
Biotech Allison DeAngelis STAT Plus: FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug
Biotech Jonathan Wosen STAT Plus: Neurocrine reports second late-stage trial success for congenital adrenal hyperplasia drug
Health Tech Mario Aguilar STAT Plus: Telehealth claims data suggest service duplication, Roche app to evaluate MS symptom
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages
Biotech Andrew Joseph STAT Plus: Kyowa Kirin to acquire Orchard Therapeutics, maker of gene therapy Libmeldy
Exclusive Jonathan Wosen STAT Plus: Failed biotech gives a rare peek inside the tough breaks — and tough choices — that led to its demise
The Pharmalot View Ed Silverman STAT Plus: Was Amgen less than forthcoming about FDA’s concerns on its cancer drug?
Health Matt Stout — Boston Globe STAT Plus: Federal bill would keep addiction medication from triggering a child abuse investigation
Biotech Eric Boodman STAT Plus: Consumer watchdog sues diagnostic firm EpicGenetics, alleging misleading claims about fibromyalgia test
Health Tech Lizzy Lawrence STAT Plus: To prevent amputation in patients with severe vascular disease, a device turns veins into arteries
Pharmalot Ed Silverman STAT Plus: FDA cites Fresenius Kabi for contamination problems that CDC linked to deadly sepsis cases